Degradable polymers are used widely in tissue engineering and regenerative medicine.
Maturing capabilities in additive manufacturing coupled with advances in orthogonal …

Currently available synthetic grafts have contributed to improved outcomes in cardiovascular
surgery. However, the implementation of these graft materials at small diameters have …

Traditional vascular grafts constructed from synthetic polymers or cadaveric human or
animal tissues support the clinical need for readily available blood vessels, but often come …

Vascular regeneration and patency maintenance, without anticoagulant administration,
represent key developmental trends to enhance small-diameter vascular grafts (SDVG) …

We developed a tissue-engineered vascular graft (TEVG) for use in children and present
results of a US Food and Drug Administration (FDA)–approved clinical trial evaluating this …

Cardiovascular diseases are a leading cause of death worldwide. Current treatments
directed at heart repair have several disadvantages, such as a lack of donors for heart …

Pathologies related to the cardiovascular system are the leading causes of death worldwide.
One of the main treatments is conventional surgery with autologous transplants. Although …

Background Tissue-engineered vascular grafts (TEVGs) have the potential to advance the
surgical management of infants and children requiring congenital heart surgery by creating …

In the field of congenital heart surgery, tissue-engineered vascular grafts (TEVGs) are a
promising alternative to traditionally used synthetic grafts. Our group has pioneered the use …

Thrombosis and stenosis remain two of the most prevalent complications of vascular
implants. The most effective strategy in clinics to inhibit stenosis is based on the eluting of …